Elite Pharmaceuticals Inc
OTC:ELTP
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
|
Elite Pharmaceuticals Inc
OTC:ELTP
|
402.9m USD |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
856.7B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
566.8B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
243.3B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.4B GBP |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
282.6B USD |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
222.2B CHF |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
237.1B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
153.4B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
115.7B USD |
Loading...
|
Market Distribution
| Min | -24 813% |
| 30th Percentile | 28.9% |
| Median | 43% |
| 70th Percentile | 60.5% |
| Max | 10 905 714.3% |
Other Profitability Ratios
Elite Pharmaceuticals Inc
Glance View
Elite Pharmaceuticals, Inc. engages in the development and manufacture of pharmacological abuse-deterrent opioid products. The company is headquartered in Northvale, New Jersey and currently employs 43 full-time employees. The company went IPO on 2014-02-20. The firm is principally engaged in the development and manufacture of oral, controlled-release products. The firm develops and manufactures generic products, products using controlled-release drug technology, products utilizing abuse deterrent technologies, and it develops and markets (either on its own or by license to other companies) generic controlled-release and abuse deterrent pharmaceutical products. Its segments include Abbreviated New Drug Applications (ANDA) for generic products and New Drug Applications (NDA) for branded products. Elite owns, licenses and contract manufactures products, including Phentermine HCl 37.5mg tablets , Phendimetrazine Tartrate 35mg tablets, Naltrexone HCl 50mg tablets, Isradipine 2.5mg and 5mg capsules, Oxycodone HCl Immediate Release 5mg, 10mg, 15mg, 20mg and 30mg tablets, Trimipramine Maleate Immediate Release 25mg, 50mg and 100mg capsules, among others.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Elite Pharmaceuticals Inc is 51.1%, which is above its 3-year median of 48.3%.
Over the last 3 years, Elite Pharmaceuticals Inc’s Gross Margin has increased from 50.3% to 51.1%. During this period, it reached a low of 44.2% on Dec 31, 2024 and a high of 55.8% on Jun 30, 2025.
